載入中
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
前收盤價
US$16.03
+US$0.57 · +3.69%
盤中時間採用ET。市場資料可能有所延遲。
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
日內區間
目前US$16.03
52週區間
目前US$16.03
盤中時間採用ET。市場資料可能有所延遲。
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
日內區間
目前US$16.03
52週區間
目前US$16.03
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 310.7萬 USD | — | 373.2萬 USD | 264.1萬 USD | 82.9萬 USD |
| 毛利 | −310.7萬 USD | — | −373.2萬 USD | −264.1萬 USD | −82.9萬 USD |
| 研究與開發 | 9285.4萬 USD | 1.15億 USD | 1.04億 USD | 1.12億 USD | 7392.2萬 USD |
| 銷售、一般及管理費用 | 3855.1萬 USD | 4172.8萬 USD | 3770.4萬 USD | 3299.3萬 USD | 2261.6萬 USD |
| 營業費用 | 1.28億 USD | 1.8億 USD | 1.38億 USD | 2.45億 USD | 1.24億 USD |
| 利息收入 | 1660.7萬 USD | 2009.3萬 USD | 1671.2萬 USD | 490.2萬 USD | 19萬 USD |
| 利息支出 | — | — | — | 2.01億 USD | — |
| 折舊和攤銷 | 310.7萬 USD | 380.5萬 USD | 373.2萬 USD | 264.1萬 USD | 82.9萬 USD |
| 營業利益 | −1.31億 USD | −1.8億 USD | −1.42億 USD | −2.47億 USD | −1.25億 USD |
| 淨利 | −1.25億 USD | −1.62億 USD | −1.25億 USD | −2.43億 USD | −1.23億 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$22.50
上漲空間 40.36%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.75億0.01%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1.31億1.33%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM9014.64萬0.12%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF5620.19萬0.06%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO3147.81萬0.23%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB2952.49萬0.28%108.2億 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA2375.05萬0.11%218.24億 USD0.03%US$32.79+0.40%
Vanguard Russell 2000 ETFVTWO2264.84萬0.12%180億 USD0.06%US$112.66+0.50%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
